(Q37614566)

21 August 2017

1 reference

title

Chemotherapy for lung cancer: the state of the art in 2009. (English)

1 reference

21 August 2017

1 reference

1 reference

Michaela J Higgins

1

1 reference

21 August 2017

David S Ettinger

series ordinal

2

1 reference

21 August 2017

publication date

1 October 2009

1 reference

Expert Review of Anticancer Therapy

21 August 2017

published in

1 reference

21 August 2017

volume

9

1 reference

21 August 2017

issue

10

1 reference

21 August 2017

page(s)

1365-1378

1 reference

Revisions in the International System for Staging Lung Cancer

21 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.115

Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.115

Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.115

Adjuvant paclitaxel plus carboplatin compared with observation in stage IB non-small-cell lung cancer: CALGB 9633 with the Cancer and Leukemia Group B, Radiation Therapy Oncology Group, and North Central Cancer Treatment Group Study Groups

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.115

Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.115

Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.115

Meta-analysis of postoperative adjuvant chemotherapy with tegafur-uracil in non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.115

DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.115

Preoperative chemotherapy followed by surgery compared with primary surgery in resectable stage I (except T1N0), II, and IIIa non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.115

A randomized trial comparing preoperative chemotherapy plus surgery with surgery alone in patients with non-small-cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.115

A randomized trial comparing perioperative chemotherapy and surgery with surgery alone in resectable stage IIIA non-small-cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.115

Randomized controlled trial of resection versus radiotherapy after induction chemotherapy in stage IIIA-N2 non-small-cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.115

Effect of preoperative chemoradiation in addition to preoperative chemotherapy: a randomised trial in stage III non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.115

Radiotherapy plus chemotherapy with or without surgical resection for stage III non-small-cell lung cancer: a phase III randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.115

Randomized phase III trial of sequential chemoradiotherapy compared with concurrent chemoradiotherapy in locally advanced non-small-cell lung cancer: Groupe Lyon-Saint-Etienne d'Oncologie Thoracique-Groupe Français de Pneumo-Cancérologie NPC 95-01 S

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.115

Phase III study of cisplatin, etoposide, and concurrent chest radiation with or without consolidation docetaxel in patients with inoperable stage III non-small-cell lung cancer: the Hoosier Oncology Group and U.S. Oncology

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.115

Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.115

Phase III randomised trial comparing paclitaxel/carboplatin with paclitaxel/cisplatin in patients with advanced non-small-cell lung cancer: a cooperative multinational trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.115

Cisplatin- versus carboplatin-based chemotherapy in first-line treatment of advanced non-small-cell lung cancer: an individual patient data meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.115

Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.115

Erlotinib in previously treated non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.115

Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.115

The differential efficacy of pemetrexed according to NSCLC histology: a review of two Phase III studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.115

Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.115

Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.115

Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.115

Phase III study of immediate compared with delayed docetaxel after front-line therapy with gemcitabine plus carboplatin in advanced non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.115

Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected].

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.115

Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.115

Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer)

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.115

Phase III study, V-15-32, of gefitinib versus docetaxel in previously treated Japanese patients with non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.115

Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.115

Randomized phase II study of gemcitabine plus cisplatin or carboplatin [corrected], with or without cetuximab, as first-line therapy for patients with advanced or metastatic non small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.115

Phase II study of paclitaxel, carboplatin, and cetuximab as first line treatment, for patients with advanced non-small cell lung cancer (NSCLC): results of OPN-017.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.115

Outcomes of patients with advanced non-small cell lung cancer treated with gefitinib (ZD1839, "Iressa") on an expanded access study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.115

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.115

Molecular predictors of response to epidermal growth factor receptor antagonists in non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.115

Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.115

Combined assessment of EGFR pathway-related molecular markers and prognosis of NSCLC patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.115

A phase II trial of gefitinib as first-line therapy for advanced non-small cell lung cancer with epidermal growth factor receptor mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.115

Prospective phase II study of gefitinib for chemotherapy-naive patients with advanced non-small-cell lung cancer with epidermal growth factor receptor gene mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.115

First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.115

Distinct epidermal growth factor receptor and KRAS mutation patterns in non-small cell lung cancer patients with different tobacco exposure and clinicopathologic features

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.115

KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.115

KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.115

The "lazarus response" in treatment-naive, poor performance status patients with non-small-cell lung cancer and epidermal growth factor receptor mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.115

First-line gefitinib for patients with advanced non-small-cell lung cancer harboring epidermal growth factor receptor mutations without indication for chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.115

Phase I/II trial evaluating the anti-vascular endothelial growth factor monoclonal antibody bevacizumab in combination with the HER-1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent non-small-cell lun

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.115

Phase II study of efficacy and safety of bevacizumab in combination with chemotherapy or erlotinib compared with chemotherapy alone for treatment of recurrent or refractory non small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.115

Sorafenib is efficacious and tolerated in combination with cytotoxic or cytostatic agents in preclinical models of human non-small cell lung carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.115

Multicenter, phase II trial of sunitinib in previously treated, advanced non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.115

Randomized Trial of Cyclophosphamide, Doxorubicin, and Vincristine Versus Cisplatin and Etoposide Versus Alternation of These Regimens in Small-Cell Lung Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.115

Cisplatin and etoposide regimen is superior to cyclophosphamide, epirubicin, and vincristine regimen in small-cell lung cancer: results from a randomized phase III trial with 5 years' follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.115

Phase III study of concurrent versus sequential thoracic radiotherapy in combination with cisplatin and etoposide for limited-stage small-cell lung cancer: results of the Japan Clinical Oncology Group Study 9104.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.115

Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission. Prophylactic Cranial Irradiation Overview Collaborative Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.115

Surgery and chemotherapy for small cell lung cancer in stages I-II with or without radiotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.115

Surgical resection of limited disease small cell lung cancer in the new era of platinum chemotherapy: Its time has come.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.115

Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.115

Randomized phase III trial comparing irinotecan/cisplatin with etoposide/cisplatin in patients with previously untreated extensive-stage disease small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.115

Phase III trial of irinotecan/cisplatin compared with etoposide/cisplatin in extensive-stage small-cell lung cancer: clinical and pharmacogenomic results from SWOG S0124.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.115

Phase II trial of irinotecan and carboplatin for extensive or relapsed small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.115

Phase II trial of gemcitabine and irinotecan in previously treated patients with small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.115

A multi-center phase II study of weekly topotecan as second-line therapy for small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.115

Multicenter phase II study of amrubicin, 9-amino-anthracycline, in patients with advanced non-small-cell lung cancer (Study 1): West Japan Thoracic Oncology Group (WJTOG) trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.115

Phase II study of amrubicin, 9-amino-anthracycline, in patients with advanced non-small-cell lung cancer: a West Japan Thoracic Oncology Group (WJTOG) study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.115

Phase II trial of amrubicin for treatment of refractory or relapsed small-cell lung cancer: Thoracic Oncology Research Group Study 0301.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.115

A genomic strategy to refine prognosis in early-stage non-small-cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.115

Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.115

Ribonucleotide reductase subunits M1 and M2 mRNA expression levels and clinical outcome of lung adenocarcinoma patients treated with docetaxel/gemcitabine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.115

Prospective Validation for Prediction of Gefitinib Sensitivity by Epidermal Growth Factor Receptor Gene Mutation in Patients with Non-Small Cell Lung Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.09.115

21 January 2018

Identifiers

DOI

10.1586/ERA.09.115

1 reference

21 August 2017

1 reference